聖濟堂(600227.SH)共有22個產品納入2019版《國家醫保目錄》
格隆匯8月22日丨聖濟堂(600227.SH)公佈,根據國家醫保局、人力資源社會保障部近日發佈的關於印發《國家基本醫療保險、工傷保險和生育保險藥品目錄》的通知(醫保發【2019】46號),公司全資子公司貴州聖濟堂製藥有限公司(“聖濟堂製藥”),共有22個產品(24個品規)納入2019 版《國家基本醫療保險、工傷保險和生育保險藥品目錄》,其中新進入品種1個(1個品規),退出品種1個(1個品規)。
公司全國獨家苗藥重樓解毒酊此前只在北京、浙江等少數地區進入地方醫保,且多年來在已進入地方醫保的地區一直保持良好的銷售態勢。此次該品種入圍2019年版國家醫保目錄,這將會在全國範圍內拓寬更多的銷售渠道。
此次聖濟堂製藥退出2019年版《國家醫保目錄》的三七片由於公司一直沒有量產,對公司的經營業績沒有影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.